Literature DB >> 23863261

Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies.

Michael Selgrad1, Julia Meissle, Jan Bornschein, Arne Kandulski, Cosima Langner, Mariya Varbanova, Thomas Wex, Ina Tammer, Dirk Schlüter, Peter Malfertheiner.   

Abstract

OBJECTIVES: Helicobacter pylori eradication rates show a constant decline over the last few years. The main reason for H. pylori treatment failure is the increasing antibiotic resistance.We assessed antibiotic susceptibility of H. pylori in a region of mid-Germany and analyzed the relationship of antibiotic resistance with the number of eradication therapies over a period of 7 years (2005-2012).
METHODS: H. pylori strains were isolated from 436 patients who underwent gastroscopy for different clinical indications. Susceptibility to amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin was determined using the E-test.
RESULTS: Primary, secondary, and tertiary resistances against clarithromycin were 7.5, 63.2, and 75.4%, respectively. Primary, secondary, and tertiary resistances to levofloxacin were 11.7, 17.6, and 36.4% and to metronidazole were 32.7, 63.2, and 80.1%, respectively. The resistance rates against tetracycline and rifabutin were comparatively low (<5%), even in patients with previous exposure to these antibiotics. Resistance to rifabutin increased to 6.2% in patients who received more than two previous eradication therapies. Amoxicillin resistance was not detectable in all patients.
CONCLUSION: In our region, we observed a stable, but constantly increasing, resistance rate to antibiotics commonly used for the treatment of H. pylori infection. Knowledge of the local antibiotic resistance rates is essential for developing successful treatment strategies for H. pylori eradication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23863261     DOI: 10.1097/MEG.0b013e3283643491

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  15 in total

Review 1.  Management of Helicobacter pylori Infection: What Should the Surgeon Know?

Authors:  Michael Selgrad; Peter Malfertheiner
Journal:  Visc Med       Date:  2017-06-16

2.  Clinical Rationale for Confirmation Testing After Treatment of Helicobacter pylori Infection: Implications of Rising Antibiotic Resistance.

Authors:  Colin W Howden; William D Chey; Nimish B Vakil
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

3.  LINE-1 hypomethylation is not a common event in preneoplastic stages of gastric carcinogenesis.

Authors:  Juozas Kupcinskas; Ruta Steponaitiene; Cosima Langner; Giedre Smailyte; Jurgita Skieceviciene; Limas Kupcinskas; Peter Malfertheiner; Alexander Link
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

Review 4.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 5.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

Review 6.  Culture-guided treatment approach for Helicobacter pylori infection: review of the literature.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Stefano Bibbò; Teresa Antonella Di Rienzo; Luca Masucci; Maurizio Sanguinetti; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 7.  Helicobacter Pylori Infection.

Authors:  Wolfgang Fischbach; Peter Malfertheiner
Journal:  Dtsch Arztebl Int       Date:  2018-06-22       Impact factor: 5.594

Review 8.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

9.  Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.

Authors:  Fernando Marcuz Silva; Elaine Cristina Silveira de Queiroz; Tomás Navarro-Rodriguez; Ricardo Correa Barbuti; Rejane Mattar; Kiyoshi Iriya; Jin Hwa Lee; Jaime Natan Eisig
Journal:  Clinics (Sao Paulo)       Date:  2015-05-01       Impact factor: 2.365

10.  Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA.

Authors:  Alexander Link; Cosima Langner; Wiebke Schirrmeister; Wiebke Habendorf; Jochen Weigt; Marino Venerito; Ina Tammer; Dirk Schlüter; Philipp Schlaermann; Thomas F Meyer; Thomas Wex; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.